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Several devices have been developed for heart failure (HF) treatment and monitor-
ing. Among device-based monitoring tools, CardioMEMSTM has received growing re-
search attention. This document reﬂects the key points of an ESC consensus meeting
on implantable devices for monitoring in HF, with a particular focus on
CardioMEMSTM.
Introduction
Heart failure (HF) is a complex disorder with haemody-
namic, neurohormonal, metabolic, functional and
electrical aspects to be considered, along with the impact
non-cardiovascular co-morbidities. In historical times, the
patient attended a physician for evaluation and the physi-
cian would examine the patient andmade special measure-
ments to determine the state of the patient sand what
treatments were needed. For HF, this was almost entirely a
haemodynamic or congestion assessment, as the only ef-
fective treatments before the 1980s were diuretics or di-
goxin. Blood pressure, heart rate, jugular venous pressure
and auscultation of the lungs were all ways the physician
would assess the patient’s haemodynamic status, supple-
mented by heart rhythm assessment. Later echocardiogra-
phy gave another window into haemodynamic assessment
offering measures of left ventricular systolic and diastolic
functions and even indirectly filling pressures and pulmo-
nary artery pressures (PAPs). Doppler techniques could be
used to estimate cardiac output. At infrequent intervals,
some invasive haemodynamic measurements could be per-
formed at cardiac catheterization to obtain direct haemo-
dynamic measures, and the future management plans of
the patient would be significantly modified after such a
haemodynamic assessment; such as a transplant eligibility
assessment.
With the advent of ACE inhibitors, ARB’s, beta-blockers
and MRA’s modifying disease outcomes without predomi-
nantly affecting haemodynamics, this “haemodynamic”
model of HF fell somewhat out of favour, and physicians be-
gan to make treatment plans based on guideline directed
medical therapy recommendations, themselves largely
based on applying the results of trial results, that did not
involve haemodynamic monitoring of HF patients.
Haemodynamic assessment thus became less frequently
used to guide most treatment decisions. The management
of HF patients at home became more driven by symptoms
and nurse evaluation or by simple monitoring techniques
such as daily weight measurements to adjust diuretic
doses.
The development of miniature implantable devices
which could measure haemodynamic variables and trans-
mit them to a monitor outside the body changed this para-
digm and offered. For the first time, a possibility for a
physician to obtain more frequent haemodynamic evalua-
tion of HF patients, and the opportunity to take these data
into account in their management decisions. The question
that arose were how would the doctor make use of these
data, and would this make a difference to the treatments
prescribed and via that mechanism would it affect long-
term patient outcomes.*Corresponding author. Email: maurizio.volterrani@sanraffaele.it
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At the time of the 2016 ESC Heart Failure Guidelines,1
the only recommendations regarding the use of implant-
able haemodynamic monitoring was that of PAP monitoring
using the CardioMEMSTM system, in which it was advised
that the use of the CardioMEMSTM system may be consid-
ered in symptomatic patients with HF with previous HF hos-
pitalization in order to reduce the risk of recurrent HF
hospitalization (with a class IIb recommendation), andmul-
tiparameter monitoring based on implanted ICD’s with this
capacity (the “IN-TIME approach”2), in which it was ad-
vised that this may be considered in symptomatic patients
with HFrEF (LVEF 35%) in order to improve clinical out-
comes, also with a class IIb recommendation. The
CHAMPION trial3,4 had shown the utility of PAP-guided HF
monitoring with the CardioMEMSTM system in high-risk HF
patients and advanced HF. The CHAMPION trial included
550 patients implanted with a permanent MEMS-based
pressure sensor in the pulmonary artery (PA) and the pri-
mary endpoint of HF-related hospitalizations at 6months
was significantly reduced [hazard ratio (HR) 0.70, 95% con-
fidence interval (CI): 0.60–0.84, P< 0.0001] and during the
entire follow-up, the treatment group had a 39% reduction
in HF-related hospitalization compared with the control
group (153 vs. 253, HR 0.64, 95% CI: 0.55–0.75; P< 0.0001).
A subsequent sub-study in 245 Medicare-eligible subjects
showedmedications were changedmore often in the treat-
ment group compared with the control group and this was
associated with an overall rate of HF hospitalizations that
was 49% lower in the treatment group (60 HF hospitaliza-
tions, 0.34 events/patient year) compared with control
(117 HF hospitalizations, 0.67 events/patient year; HR
0.51, 95% CI: 0.37–0.70; P< 0.0001) along with a 58% re-
duction in all-cause 30 day readmissions.5 It appears also to
be effective in HFpEF.6 However, the implementation of
this device in routine practice remains challenging, be-
cause of the cost7 and the need for an infrastructure to be
able to receive the daily measurements and to respond to
them in a timely fashion, not least the issue of whose re-
sponsibility is to capture and respond to these new data
and how that effort is to be funded within the local health
care system. For example, in many European Countries,
there is no reimbursement for the workload involved in
monitoring patients with implantable devices.
An alternative approach, that of an implantable right
ventricular (RV) pressure monitoring failed to reduce HF
hospitalizations significantly in a smaller trial (COMPASS-
HF) compared with CHAMPION.8 The IN-TIME trial studied
HF patients with a recent dual-chamber ICD or CRT-D im-
plantation. After a 1 month run-in phase, patients were
randomly assigned (1:1) to either automatic, daily,
implant-based, multiparameter telemonitoring in addition
to standard care or standard care without telemonitoring.
The primary outcome (death or, HF hospitalization, or
change in either NYHA class or patient global self-
assessment) was significantly improved, 63 (18.9%) of 333
vs. 90 (27.2%) of 331 in the control group (P¼ 0.013, odds
ratio 0.63, 95% CI: 0.43–0.90) along with 10 vs. 27 deaths
during follow-up. The basis of these results appears to be
that blood volume expansion, and incipient pulmonary oe-
dema may start many days before classical decompensa-
tion symptoms or even weight changes occur, and thus
monitoring physiologic signals from implanted devices may
provide earlier warning of impending decompensation epi-
sodes, facilitating diuretic or haemodynamically acting
drug interventions.9 An alternative approach is that of im-
plantable impedance monitors that can detect fluid vol-
umes in the thorax and lung. In the Fluid Accumulation
Status Trial (FAST) study, 156 HF patients had their ICD or
CRT-D devices modified to record daily intrathoracic im-
pedance. In these patients, 40 HF events of a total of 65
were detected by impedance but not by body weight
changes, whereas only five were detected by weight
changes but not by impedance measure.10 The SENSE-HF
trial, however, using a similar approach showed in 501 HF
patients showed this had low sensitivity (20.7%) and posi-
tive predictive accuracy (4.7%) for detecting HF hospital-
izations.11 Also the OptiLink HF (Optimization of Heart
Failure Management using OptiVolTM Fluid Status
Monitoring and CareLinkTM) study of whether automated
fluid status (implantable impedance monitor) alert notifi-
cation via telemedicine improves outcome in 1002 HF
patients was neutral in its primary Endpoint (CV death or
CV hospitalization) with 45.0% active vs. 48.1% in the con-
trol arm [HR, 0.87; 95% CI: 0.72–1.04; P¼ 0.13] 59 (11.7%)
vs. 63 (12.7%) deaths (HR, 0.89; 95% CI: 0.62–1.28;
P¼ 0.52). It was noteworthy that 24% of alerts were not
transmitted and only 30% were followed by amedical inter-
vention, indicating the need for the health care system to
be able and ready to act on the data transmitted. The
EVOLVO study showed in 200 HF patients that audible
alarms at home in patients with ICD’s lead to more hospital
or clinic visits compared with patients with the alarm inac-
tivated and the notification being sent wirelessly to the
hospital/clinic instead12 with 75 emergency department/
urgent in-office visits for HF, arrhythmias or ICD-related
events in the remote arm vs. 117 in the standard arm (0.59
vs. 0.93 events per year; incident rate ratio [IRR], 0.65;
95% CI: 0.49–0.88; P¼ 0.005). The much larger REM-HF
study in 1650 HF patients using multiple manufacturers’
implantable devices, however, failed to a show a reduction
in the combined endpoint of death or CV hospitalization
[349 patients (42.4%) in the RM group and in 347 patients
(40.8%) in the UC group (HR 1.01; 95% CI: 0.87–1.18;
P¼ 0.87)]. The devices were CRT, CRT-P or CRT-D or ICD
and the trial involved weekly data downloads from the
patients’ devices with simultaneous review by remote
monitors.
Other approaches that have been tested include im-
plantable left atrial pressure monitoring, but one
study was stopped early due to procedure-related
complications.13 Another trial (REDUCE-HF) with an im-
plantable haemodynamic monitor ceased premature due
to haemodynamic RV pressure lead problems.14 Ultimately
any such device needs to show it can improve outcomes,
which will require specifically designed trials.15
The management of cardiac arrhythmia and advanced
HF syndromes is particularly challenging. For these rea-
sons, the use of cardiac implantable electronic devices is
pivotal in HF management and monitoring. Main applica-
tions of device therapy in HF are cardiac resynchronization
therapy and treatment of ventricular tachycardia or fibril-
lation for prevention of sudden cardiac death.16 Beyond
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treatment, devices are used in HF monitoring although
their implementation is still challenging.
For this reason, a multidisciplinary panel of leading in-
ternational experts has been organized by the ESC to dis-
cuss the issues related to physiological monitoring of HF
using implantable devices. The key points of the meeting
are reflected in this document.
CardioMEMSTM
Many devices are currently approved for clinical use or are
under investigational use for the monitoring of HF.17
Device-based monitoring tools are classified into PAP moni-
tor, RV monitor (the ChronicleTM; Medtronic Inc.,
Minneapolis, MN, USA), left atrial pressure monitor
(HeartPODTM), intrathoracic impedance monitor [The
Medtronic Inc. OptiVol Fluid Status Monitor and the St.
Jude Medical (SJM) CorVueTM Congestion Monitor] and Lung
Fluid monitor (ReDS; Sensible Medical Innovations Ltd,
Netanya, Israel).
So far, the only FDA-approved remote monitoring system
for patients with HF is Cardio-Microelectro-mechanical sys-
tem (CardioMEMSTM; Abbott, Sylmar, CA, USA). This is an
implantable PAP monitoring device that allows a direct
monitoring of the PAP via a sensor implanted in the PA.2
The sensor monitors changes in the PAPs and communicates
via wireless to an external analyser. This information is
then uploaded to a web-based interface from which
healthcare providers can track the results and manage
patients.1,2
The ongoing prospective, observational MEMS-HF study18
will evaluate the safety and feasibility of CardioMEMSTM
system in Europe, shedding new light on the utility of
haemodynamic-guided HF management in improving clini-
cal outcomes.
Future directions
Detailed recommendations for standardized, structured
post-implant HF care, and for the management of ambula-
tory PAP trends are needed.
Reductions in HF-related hospitalizations are achievable
by novel device-based telemonitoring strategies, that
should be feasible at little extra cost.
Such a novel diagnostic adjunct should be incorporated
into existing HF disease management strategies. Patients
should be monitored using individualized PAP thresholds to
trigger medication adjustments during follow-up by specif-
ically trained nurses in a multidisciplinary HF management
for all patients with advanced HF. Thus, beyond reimburse-
ment, in order to improve the implementation of device
therapy in routine clinical practice, training/education of
specialized team is required.
Conflicts of interest: none declared.
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